Poor Psychological Outcomes Seen for Patients With Rare Cancers
By Elana Gotkine HealthDay Reporter
MONDAY, Aug. 19, 2024 -- Patients with rare cancers have poor psychological outcomes, according to a review and meta-analysis published in the June issue of eClinicalMedicine.
Chen Ee Low, from the School of Medicine at the National University of Singapore, and colleagues conducted a systematic review to examine the psychological outcomes of patients with rare cancers. All peer-reviewed English language studies published since 2000 to Jan. 30, 2024, that evaluated the prevalence, incidence, and risk for depression, anxiety, suicide, and posttraumatic stress disorder (PTSD) in patients with rare cancers were included (32 studies; 57,470 patients).
The researchers identified a significant increased risk-ratio of depression and anxiety (risk ratios, 2.61 and 2.66, respectively) for patients with rare cancer versus healthy controls. The incidence of suicide was high (315 per 100,000 person-years), as were the prevalence rates of depression, anxiety, and PTSD (17, 20, and 18 percent, respectively). Suicide incidence and PTSD prevalence were significantly higher for patients with rare cancers versus those with common cancer types. Risk factors for negative psychological outcomes included having advanced disease, chemotherapy treatment, and lower income and social status.
"We emphasize the critical imperative for early detection and increased support for this vulnerable group," the authors write. "Urgent interventions and further research are warranted to elucidate additional risk and protective factors to devise targeted strategies to alleviate the burden of depression and anxiety in these vulnerable individuals."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Addictive Screen Use Tied to Suicidal Behaviors in Early Adolescence
FRIDAY, June 27, 2025 -- Both high and increasing addictive screen use trajectories are associated with suicidal behaviors and worse mental health in early adolescence, according...
Telehealth Intervention Beneficial for Seniors With Metastatic Cancer
WEDNESDAY, June 25, 2025 -- The telehealth-administered Geriatric Assessment–Guided Intervention (GAIN-S) improves physical function, mood, quality of life, and prognostic...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.